274 related articles for article (PubMed ID: 8063025)
21. The release of gastric inhibitory peptide, glucagon-like peptide-I, and insulin after oral glucose test in colectomized subjects.
Palnaes Hansen C; Andreasen JJ; Holst JJ
Scand J Gastroenterol; 1997 May; 32(5):473-7. PubMed ID: 9175210
[TBL] [Abstract][Full Text] [Related]
22. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection.
Miholic J; Orskov C; Holst JJ; Kotzerke J; Pichlmayr R
Digestion; 1993; 54(2):73-8. PubMed ID: 8319842
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
24. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
Salehi M; Gastaldelli A; D'Alessio DA
Gastroenterology; 2014 Mar; 146(3):669-680.e2. PubMed ID: 24315990
[TBL] [Abstract][Full Text] [Related]
25. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
26. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
Fukase N; Takahashi H; Manaka H; Igarashi M; Yamatani K; Daimon M; Sugiyama K; Tominaga M; Sasaki H
Diabetes Res Clin Pract; 1992 Mar; 15(3):187-95. PubMed ID: 1576919
[TBL] [Abstract][Full Text] [Related]
27. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
28. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia.
Ahrén B; Holst JJ
Diabetes; 2001 May; 50(5):1030-8. PubMed ID: 11334405
[TBL] [Abstract][Full Text] [Related]
29. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
30. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
31. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
32. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Orskov C; Jeppesen J; Madsbad S; Holst JJ
J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
[TBL] [Abstract][Full Text] [Related]
33. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
34. Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery.
Roberts GP; Kay RG; Howard J; Hardwick RH; Reimann F; Gribble FM
Surg Obes Relat Dis; 2018 May; 14(5):562-568. PubMed ID: 29548882
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic alpha-cell function in idiopathic reactive hypoglycemia.
Ahmadpour S; Kabadi UM
Metabolism; 1997 Jun; 46(6):639-43. PubMed ID: 9186298
[TBL] [Abstract][Full Text] [Related]
36. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
[TBL] [Abstract][Full Text] [Related]
37. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
38. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
[TBL] [Abstract][Full Text] [Related]
39. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis.
Kruszynska YT; Ghatei MA; Bloom SR; McIntyre N
Hepatology; 1995 Apr; 21(4):933-41. PubMed ID: 7705803
[TBL] [Abstract][Full Text] [Related]
40. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
